|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, July 29, 2020 ) The Amniotic Products Market growth is largely driven by factors such as growth in the target patient population, the rising incidence of burn injuries, awareness programs for wound care treatment and management, and the rise in venture capital funding and government investments. The emerging economies and the implementation of the 21st Century Cures Act are expected to provide a wide range of growth opportunities for players in the market.
How the Market Growth looks like and Industry Segmentation?
The Global Amniotic Products Market is projected to reach USD 1,095 million by 2025 from USD 748 million in 2020, at a CAGR of 7.9%
On the basis of type, the amniotic Amniotic Membranes market is categorized into two segments, amniotic membranes and amniotic suspensions. The amniotic membranes segment accounted for the largest share of the market in 2019. It is also projected to record the highest CAGR during the forecast period. Amniotic membranes have anti-inflammatory, anti-angiogenic, anti-fibrotic, and anti-microbial properties. These benefits of amniotic membranes support their adoption. This is a major factor driving market growth.
Based on end user, the amniotic products market is segmented into hospitals & ASCs and other end users. In 2019, hospitals & ASCs accounted for the largest share of the market. Factors such as the high demand for wound care biologics (including amniotic tissue products) in hospitals and ASCs, the high patient inflow in this care setting, and the availability of reimbursements are driving the growth of this segment.
Browse 101 market data tables and 29 figures spread through 126 pages and in-depth TOC - Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=191575976
Recent Developments:
- In 2019, Smith & Nephew acquired Osiris Therapeutics, complementing the company’s advanced wound management unit by offering regenerative medicine products inclusive of skin, bone graft, and articular cartilage substitutes.
- In 2018, the US FDA granted the Regenerative Medicine Advanced Therapy (RMAT) designation to MiMedx’s AmnioFix Injectable for use in the treatment of osteoarthritis (OA) of the knee.
- In 2017, Organogenesis acquired NuTech to support the firm’s development of next-generation amniotic products. The newly-combined company offers a portfolio of advanced next-generation products for the wound care and surgical biologics markets.
Key Questions Addressed by the Report:
- Where will all these developments take the industry in the mid-to-long term?
- What are the recent trends affecting the amniotic products market?
- Who are the major end users in the amniotic products market?
- Who are the key players in the market, and how intense is the competition?
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=191575976
Geographical Regions Mapped in Report:
The global Amniotic Membranes Market has been divided into four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America accounted for the largest share of the global amniotic products market in 2019. This can be attributed to the high prevalence of target diseases, increasing geriatric population, rising awareness about advanced treatment options, and the strong presence of key market players of amniotic products. The presence of a well-established healthcare system and ongoing investments by hospitals to upgrade & expand their operating capabilities are other factors supporting market growth in North America.
Major Key Players Mapped in Research Report:
The prominent players operating in this market include MiMedx (US), Smith & Nephew (UK), Organogenesis (US), and Integra LifeSciences Corporation (US). Other players include Stryker Corporation (US), Wright Medical (Netherlands), Applied Biologics (US), Celularity (US), Katena Products (US), Lucina BioSciences (US), Next Biosciences (South Africa), Skye Biologics (US), Surgenex (US), TissueTech (US), Ventris Medical (US), StimLabs (US), VIVEX Biologics (US), LifeCell International (India), NuVision Biotherapies (England), and Genesis Biologics (US).
MarketsandMarkets™
Mr. Aashish Mehra
1-888-600-6441
raviraj.tak@marketsandmarkets.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
